

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/613,414 07/03/2003		07/03/2003	Natesan Selvakumar	U 014698-7	7273	
140	7590	01/24/2005		EXAMINER		
LADAS &		r.m	SHAMEEM, GOLAM M			
26 WEST 61ST STREET NEW YORK, NY 10023				ART UNIT	PAPER NUMBER	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				1626	1626	

DATE MAILED: 01/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
	Office Author Occurs	10/613,414	SELVAKUMAR ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Golam M M Shameem	1626				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE - Exte after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RE MAILING DATE OF THIS COMMUNICATIC maintenance may be available under the provisions of 37 CFI SIX (6) MONTHS from the mailing date of this communication a period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory pere to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	NN. R 1.136(a). In no event, however, may a reply b reply within the statutory minimum of thirty (30) find will apply and will expire SIX (6) MONTHS f	e timely filed days will be considered timely. rom the mailing date of this communication. DNED (35 U.S.C. & 133)				
Status							
1)🖂	Responsive to communication(s) filed on 1	5 November 2004.					
2a)□	This action is FINAL . 2b)⊠ 1	This action is non-final.					
3)[Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
5)□ 6)⊠ 7)□	Claim(s) 1-87 is/are pending in the applicat 4a) Of the above claim(s) 9-78 and 80-87 is Claim(s) is/are allowed. Claim(s) 1-8 and 79 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction an	/are withdrawn from consideration	1.				
Applicati	on Papers						
9)[The specification is objected to by the Exam	niner.					
	☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)	The oath or declaration is objected to by the	Examiner. Note the attached Offi	ce Action or form PTO-152.				
Priority u	ınder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) □ All b) □ Some * c) □ None of: 1. □ Certified copies of the priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No. 10/032,392. 3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
Attachment	• •						
2) 🔲 Notice 3) 🔯 Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/ No(s)/Mail Date 8/25/03	4) Interview Summa Paper No(s)/Mail 08) 5) Notice of Informa 6) Other:					

Art Unit: 1626

DETAILED ACTION

Priority

This application is a CIP of 10/032,392 12/21/2001 and the claim of foreign priority under 35 U.S.C. § 119(a)-(d) to India 1124/MAS/2000 12/26/2000 is acknowledged.

Status of Claims

Claims 1-87 are currently pending in the application.

Receipt is acknowledged of amendment / response filed on November 15, 2004 and that has been entered.

Claims 9-78 and 80-87 are withdrawn from further consideration pursuant to 37 C.F.R. 1.142 (b) as being drawn to a non-elected subject matter.

Information Disclosure Statement

Receipt is acknowledged of Information Disclosure Statement (IDS), filed on 08/25/2003, which has been entered in the file.

Response to Election/Restriction

In response to the restriction requirement, Applicants have elected Group I, which includes claims 1-8, and 79 drawn to a compound and composition with traverse is acknowledged. The traversal is on the ground(s) that all the pending claims should be rejoined and examined with the elected Group I "because of the overlap between claim 1 and 9" (Remarks, page 2) and therefore a search and examination of the entire Markush group should be made without serious burden.

The Examiner respectfully disagrees with the Applicants because the products of Invention groups I-V differ materially in structure and in element from each other and therefore,

Application/Control Number: 10/613,414

Art Unit: 1626

are capable of supporting their own patents. The invention groups I-V are related to a set of structurally diverse compounds, process for preparing and their methods of use (chemical structures, which are similar, are presumed to function similarly, whereas chemical structures that are not similar are not presumed to function similarly), which do not possess a substantial common core wherein a reference anticipating one would not necessarily render the other obvious and to search all the above groups in a single application would be an undue burden on the Examiner. Because of many classes and subclasses in each of the Group, a separate search considerations are involved, which would impose a serious burden on the Examiner to perform a complete search of the defined areas if unrestricted. Also the fields of search are not coextensive. The wide disparity among the groups requires that many divergent fields must be searched, including all classes and subclasses of U.S. and foreign patents as well as journals and publications. Moreover, the Examiner must perform a commercial database search on the subject matter of each group in addition to a paper search, which is quite burdensome to the Examiner. However, Examiner may reconsider to rejoin method of use claims or process of making claims commensurate in scope with the product claims when the case would be found in condition for allowance [provided those method claims or process claims are free from 35 U.S.C. §112 first (including written description, reach-through claim language and/or scope-enablement issues) and second paragraphs]. For these reasons, Applicant's arguments are found unpersuasive and, therefore, the requirement for restriction and election of species is still deemed proper.

Page 3

Applicants preserve their right to file a divisional on the non-elected subject matter.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11

Art Unit: 1626

F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-8 and 79 are rejected under the judicially created doctrine of obviousness-type double patenting, as being unpatentable over claims 1-20 and 31-56 of co-pending Application No. 10/632,950 and also over claims 1, 2, 4-20, 31-38 and 41-51 of co-pending Application No. 10/032,392. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to the same art recognized subject matter. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The compounds taught by co-pending application are similar to instant application because a reference anticipating one set of claims will render the other obvious and it would have been obvious to one of ordinary skill in the art at the time of the invention was made since Selvakumar et al teach the generic compounds and compositions which are similar to the instantly claimed compounds and compositions. The disclosure of Selvakumar et al that teach many combinations (including various substitutions, such as Z represents O, S, =CH, -CH₂ or NR^b), which would easily place Applicants invention in possession of the public at the time of Applicants invention was filed. Therefore, in the instant case, one skilled in the chemical art would be motivated to choose to replace variable substitutions (such as R¹ is NHR⁴ and Z is NR^b or any other indicated obvious variables) in core heterocyclic ring in view of the known teaching of the art. The claimed compounds are so closely related structurally to the homologous and /or analogous compounds of the reference as

to be structurally obvious therefore in the absence of any unobviousness or unexpected properties. Moreover, any other differences are but obvious structural modifications, which would be apparent to one skilled in the chemical art that can use similar substitutions, would expect to have the same or essentially the same results. Therefore, in looking at the instant claimed compounds as a whole, the claimed compounds would have been suggested to one skilled in the art unless unobvious or unexpected results can be shown.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 6:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached at (571) 272-0699. The Unofficial fax phone number for this Group is (703) 308-7921. The Official fax phone numbers for this Group are 571-273-8300.

When filing a FAX in Technology Center 1600, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [joseph.mcKane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet

Art Unit: 1626

e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600.

Golam M M Shameem, Ph.D. Primary Patent Examiner

Art Unit 1626, Group 1600

Technology Center 1

January 18, 2005